New trial
Phase 1 Trial of Cosibelimab and Balixafortide Targeting PD-L1 and CXCR4 in Metastatic PDAC
- Trial ID
- NCT06981806 on ClinicalTrials.gov
- Cancer type
- Pancreatic Cancer
- Published in
- New in Oncology - June 6, 2025
An open-label phase 1 study at Cedars-Sinai is evaluating the safety and tolerability of cosibelimab—a PD-L1 directed monoclonal antibody—and balixafortide, a CXCR4 inhibitor, in metastatic pancreatic ductal adenocarcinoma after progression on standard chemotherapy.
More in pancreatic cancer
-
Trial result · Oct 15, 2026 · NCT04543071
Motixafortide (CXCR4 inhibitor) + cemiplimab (PD-1) + gem/nab-paclitaxel posts 55% confirmed ORR in 1L metastatic PDAC -
Trial result · Oct 15, 2026 · NCT06850623
ACT (PS101 + focused ultrasound) plus mFOLFIRINOX shows early responses and a resection conversion signal in locally advanced/borderline PDAC -
Trial result · Oct 15, 2026 · NCT07562152
Atebimetinib (deep cyclic MEK inhibitor) + mGnP links weight preservation to longer OS in 1L pancreatic cancer -
New trial · Oct 15, 2026 · NCT07619521
Phase 1/2 selumetinib plus trastuzumab deruxtecan targets KRAS-mutant, HER2-expressing pancreatic cancer -
New trial · Oct 15, 2026 · NCT07824960
Phase 1b/2 avutometinib plus defactinib adds RAF/MEK and FAK inhibition to mFOLFIRINOX in pancreatic cancer